← Back to Search

CCR5 Antagonist

Maraviroc for Stroke(CAMAROS Trial)

University of British Columbia & GF Strong Rehabilitation Centre, Vancouver, Canada
Maraviroc +4 morePhase 2RecruitingLed by Sean Dukelow, MD PhD FRCPCResearch Sponsored by University of Calgary

CAMAROS Trial Summary

This trial is testing whether a CCR5 antagonist coupled with exercise can improve upper and lower extremity recovery after a stroke.

CAMAROS Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have had a certain type of stroke in the front part of your brain.
You are 18 years old or older.
You have weakness on one side of your body that requires inpatient rehabilitation.
You can move your shoulder or hip in specific ways.
For the upper extremity group, you need to have a certain level of strength in your shoulder and fingers, and a specific score on an assessment test.
People who need help from two others to move or walk very slowly with limited hip movement.

CAMAROS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (between 5 days and 6 weeks after stroke), after 8 weeks on drug/placebo, and 6-months post-stroke
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (between 5 days and 6 weeks after stroke), after 8 weeks on drug/placebo, and 6-months post-stroke for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in 10-Meter Walk Test Score
Change in Fugl-Meyer Upper Extremity Assessment Score
Secondary outcome measures
6 Minute Walk Test
Upper arm
Other outcome measures
European Quality of Life Across 5 Domains (EQ-5D)
Fugl-Meyer Lower Extremity Assessment Score
Montreal Cognitive Assessment (MoCA)
+4 more

Side effects data

From 2008 Phase 4 trial • 18 Patients • NCT00666705
Peripheral neurophathy
Study treatment Arm
Maraviroc + Raltegravir

CAMAROS Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Maraviroc (Celsentri)Experimental Treatment4 Interventions
Maraviroc (Celsentri) will be administered to this group. Participants will be administered a dose of 300mg to be taken twice per day for the duration of the exercise intervention (8 weeks).
Group II: PlaceboPlacebo Group4 Interventions
An over-encapsulated placebo, or "sugar pill" (so it appears identical to the trial drug) will be administered to this group. Participants will be administered the placebo identical to the 300mg maraviroc tablet for the duration of the exercise intervention (8 weeks).
First Studied
Drug Approval Stage
How many patients have taken this drug
Motor Learning
Exercise Program
Completed Phase 3
Completed Phase 4

Find a Location

Who is running the clinical trial?

Dalhousie UniversityOTHER
159 Previous Clinical Trials
340,357 Total Patients Enrolled
6 Trials studying Stroke
910 Patients Enrolled for Stroke
Parkwood Hospital, London, OntarioOTHER
6 Previous Clinical Trials
598 Total Patients Enrolled
3 Trials studying Stroke
463 Patients Enrolled for Stroke
Memorial University of NewfoundlandOTHER
64 Previous Clinical Trials
1,765,175 Total Patients Enrolled
1 Trials studying Stroke
52 Patients Enrolled for Stroke

Media Library

Maraviroc (CCR5 Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT04789616 — Phase 2
Stroke Research Study Groups: Maraviroc (Celsentri), Placebo
Stroke Clinical Trial 2023: Maraviroc Highlights & Side Effects. Trial Name: NCT04789616 — Phase 2
Maraviroc (CCR5 Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04789616 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the Maraviroc's standing with the FDA?

"Maraviroc's safety is only supported by Phase 2 trial data, which means that while there is some evidence of its safety, there is none for its efficacy. Thus, we've given it a score of 2."

Answered by AI

What other research studies have included Maraviroc as a treatment?

"Maraviroc was first studied in 2009 at IRCCS Ospedale Pediatrico Bambino Gesu. To date, 18399 trials have been completed while 5 studies are still recruiting patients. These clinical trials tend to be based in Vancouver, Canada."

Answered by AI

How many test subjects are required for this experiment?

"This particular study has completed recruitment for patients. The trial was posted on May 1st, 2022 and updated two days later. However, there are presently 1085 clinical trials actively searching for patients with stroke and 5 trials for Maraviroc that still require participants."

Answered by AI

Are participants still being signed up for this experiment?

"This study is not currently looking for more patients. It was originally posted on May 1st, 2022 and last updated on the second of the same month. There are 1085 other trials related to stroke that are still recruiting patients, as well as 5 studies centred around Maraviroc."

Answered by AI

Is this a groundbreaking new study?

"At this moment in time, there are 5 ongoing clinical trials involving Maraviroc taking place in 27 cities and 12 countries. The first study was completed in 2009 by ViiV Healthcare. A total of 103 patients were used in the Phase 2 drug approval stage trial. In the 11 years since 2009, a grand total of 18399 additional trials have been conducted."

Answered by AI

Who else is applying?

What state do they live in?
District of Columbia
How old are they?
18 - 65
What site did they apply to?
Riverview Health Centre
Sunnybrook Health Sciences Centre
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria

How responsive is this trial?

Typically responds via
Most responsive sites:
  1. Sunnybrook Health Sciences Centre: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
~55 spots leftby Dec 2024